Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 530

1.

Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.

Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R; RENAL Replacement Therapy Study Investigators.

Crit Care Med. 2012 May;40(5):1523-8. doi: 10.1097/CCM.0b013e318241e553.

PMID:
22511133
2.
3.

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J.

Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.

PMID:
19237898
4.

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ.

Crit Care. 2013 May 3;17(3):R84. doi: 10.1186/cc12705.

5.

Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Bauer SR, Salem C, Connor MJ Jr, Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH.

Clin J Am Soc Nephrol. 2012 Mar;7(3):452-7. doi: 10.2215/CJN.10741011. Epub 2012 Jan 26.

6.

Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.

Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2014 Apr;43(4):343-8. doi: 10.1016/j.ijantimicag.2014.01.009. Epub 2014 Feb 10.

PMID:
24612982
7.

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.

Crit Care Med. 2008 May;36(5):1500-6. doi: 10.1097/CCM.0b013e318170ba21.

PMID:
18434883
8.

Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.

Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A.

Intensive Care Med. 1999 Oct;25(10):1100-4.

PMID:
10551965
9.

Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.

Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.

Pharmacotherapy. 2015 Jun;35(6):600-7. doi: 10.1002/phar.1604.

PMID:
26095008
10.

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.

J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.

PMID:
23908259
11.

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Dulhunty J, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Roberts JA; DALI Study Group.

J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3.

PMID:
26433783
12.

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.

Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G.

Clin Pharmacol Ther. 1999 Jan;65(1):50-7.

PMID:
9951430
13.

Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.

Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A.

Crit Care Med. 2000 Mar;28(3):632-7.

PMID:
10752806
14.

Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.

Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT.

Crit Care Med. 2000 Oct;28(10):3412-6.

PMID:
11057794
15.

Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.

Petersson J, Giske CG, Eliasson E.

Acta Anaesthesiol Scand. 2016 Nov;60(10):1425-1436. doi: 10.1111/aas.12808. Epub 2016 Sep 21.

PMID:
27655029
16.

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F.

Crit Care. 2010;14(4):R126. doi: 10.1186/cc9091. Epub 2010 Jul 1.

17.

Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.

Connor MJ Jr, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH.

Antimicrob Agents Chemother. 2011 Feb;55(2):557-60. doi: 10.1128/AAC.00548-10. Epub 2010 Nov 29.

18.

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J.

Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16.

PMID:
20018492
19.

Case-control study of drug monitoring of β-lactams in obese critically ill patients.

Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F.

Antimicrob Agents Chemother. 2013 Feb;57(2):708-15. doi: 10.1128/AAC.01083-12. Epub 2012 Nov 12.

20.

Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.

Cies JJ, Shankar V, Schlichting C, Kuti JL.

Pediatr Infect Dis J. 2014 Feb;33(2):168-73. doi: 10.1097/INF.0b013e3182a743c7.

PMID:
23907263

Supplemental Content

Support Center